BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 30423270)

  • 1. Treatment of Acute Promyelocytic Leukemia in Adults.
    Osman AEG; Anderson J; Churpek JE; Christ TN; Curran E; Godley LA; Liu H; Thirman MJ; Odenike T; Stock W; Larson RA
    J Oncol Pract; 2018 Nov; 14(11):649-657. PubMed ID: 30423270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial.
    Zhang X; Zhang H; Chen L; Wang M; Xi J; Liu X; Xie M; Li D; Gulati ES; Gong S; Wang H
    Trials; 2018 Sep; 19(1):476. PubMed ID: 30185214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial.
    Zhang L; Zou Y; Chen Y; Guo Y; Yang W; Chen X; Wang S; Liu X; Ruan M; Zhang J; Liu T; Liu F; Qi B; An W; Ren Y; Chang L; Zhu X
    BMC Cancer; 2018 Apr; 18(1):374. PubMed ID: 29615003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcome of relapsed acute promyelocytic leukemia treated with oral arsenic trioxide-based reinduction and maintenance regimens: A 15-year prospective study.
    Gill H; Yim R; Lee HKK; Mak V; Lin SY; Kho B; Yip SF; Lau JSM; Li W; Ip HW; Hwang YY; Chan TSY; Tse E; Au WY; Kumana CR; Kwong YL
    Cancer; 2018 Jun; 124(11):2316-2326. PubMed ID: 29579321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.
    Zhu HH; Wu DP; Du X; Zhang X; Liu L; Ma J; Shao ZH; Ren HY; Hu JD; Xu KL; Wang JW; Song YP; Fang MY; Li J; Yan XY; Huang XJ
    Lancet Oncol; 2018 Jul; 19(7):871-879. PubMed ID: 29884593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care.
    Iland HJ; Wei A; Seymour JF
    Best Pract Res Clin Haematol; 2014 Mar; 27(1):39-52. PubMed ID: 24907016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How to manage acute promyelocytic leukemia.
    Mi JQ; Li JM; Shen ZX; Chen SJ; Chen Z
    Leukemia; 2012 Aug; 26(8):1743-51. PubMed ID: 22422168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal treatment strategies for high-risk acute promyelocytic leukemia.
    Norsworthy KJ; Altman JK
    Curr Opin Hematol; 2016 Mar; 23(2):127-36. PubMed ID: 26825698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxide plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid.
    Autore F; Chiusolo P; Sorà F; Giammarco S; Laurenti L; Innocenti I; Metafuni E; Piccirillo N; Pagano L; Bacigalupo A; Leone G; Sica S
    Leuk Lymphoma; 2019 May; 60(5):1328-1330. PubMed ID: 30526180
    [No Abstract]   [Full Text] [Related]  

  • 10. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
    Lo-Coco F; Avvisati G; Vignetti M; Thiede C; Orlando SM; Iacobelli S; Ferrara F; Fazi P; Cicconi L; Di Bona E; Specchia G; Sica S; Divona M; Levis A; Fiedler W; Cerqui E; Breccia M; Fioritoni G; Salih HR; Cazzola M; Melillo L; Carella AM; Brandts CH; Morra E; von Lilienfeld-Toal M; Hertenstein B; Wattad M; Lübbert M; Hänel M; Schmitz N; Link H; Kropp MG; Rambaldi A; La Nasa G; Luppi M; Ciceri F; Finizio O; Venditti A; Fabbiano F; Döhner K; Sauer M; Ganser A; Amadori S; Mandelli F; Döhner H; Ehninger G; Schlenk RF; Platzbecker U; ; ;
    N Engl J Med; 2013 Jul; 369(2):111-21. PubMed ID: 23841729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JSH guideline for tumors of hematopoietic and lymphoid tissues: leukemia: 2. Acute promyelocytic leukemia (APL).
    Asou N; Fujita H; Shinagawa K
    Int J Hematol; 2017 Oct; 106(4):459-470. PubMed ID: 28856623
    [No Abstract]   [Full Text] [Related]  

  • 12. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.
    Leu L; Mohassel L
    Am J Health Syst Pharm; 2009 Nov; 66(21):1913-8. PubMed ID: 19850784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA.
    Ghavamzadeh A; Jalili M; Rostami S; Yaghmaie M; Aliabadi LS; Mousavi SA; Vaezi M; Fumani HK; Jahani M; Alimoghaddam K
    Leuk Res; 2018 Mar; 66():85-88. PubMed ID: 29407588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upfront maintenance therapy with arsenic trioxide in acute promyelocytic leukemia provides no benefit for non-t(15;17) subtype.
    Chiang YH; Chang YF; Hsieh RK; Lin J; Chen CG; Lim KH; Lin HC; Chang MC
    Asia Pac J Clin Oncol; 2012 Dec; 8(4):330-6. PubMed ID: 22897350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal approach for high-risk acute promyelocytic leukemia.
    Iland HJ; Seymour JF; Wei A
    Curr Opin Hematol; 2014 Mar; 21(2):102-13. PubMed ID: 24378704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conventional induction and post-remission therapy in APL: have we arrived?
    Sanz MA; Iacoboni G; Montesinos P
    Best Pract Res Clin Haematol; 2014 Mar; 27(1):33-8. PubMed ID: 24907015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experience.
    Cheng Y; Zhang L; Wu J; Lu A; Wang B; Liu G
    Eur J Haematol; 2013 Dec; 91(6):483-9. PubMed ID: 24033687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Acute promyelocytic leukemia: state-of-the-art management].
    Asou N
    Rinsho Ketsueki; 2018; 59(6):725-734. PubMed ID: 29973452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
    Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
    Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
    Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
    Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.